SCHEMBL6691677

SCHEMBL6691677

COc1ccccc1[C@H](O)COc1ccc(CCNC[C@H](O)c2ccc(O)c(NC=O)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 15/20 0.70
ADRB3 P13945 9/20 0.63
ADRB1 P08588 6/20 0.63
DRD2 P14416 4/20 0.54
DRD3 P35462 3/20 0.54
PGR P06401 1/20 0.54
SLC6A4 P31645 1/20 0.54
ADRA1A P35348 1/20 0.54
PTGS2 P35354 1/20 0.54
SLC6A3 Q01959 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
CYP2C19 P33261 1/20 0.54
DRD1 P21728 2/20 0.51
DRD4 P21917 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6141170 1.00 ADRB2 (0.70) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL6691687 1.00 ADRB2 (0.70) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL6695265 0.87 ADRB2 (0.81) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL6695262 0.87 ADRB2 (0.81) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL6141541 0.87 ADRB2 (0.81) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL30254965 0.85 ADRB2 (0.77) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL14260754 0.85 ADRB2 (0.77) ADRB2ADRB3ADRB1DRD2DRD3
SCHEMBL6141477 0.85 ADRB2 (0.76) ADRB2ADRB3ADRB1
SCHEMBL6141482 0.85 ADRB2 (0.76) ADRB2ADRB3ADRB1
SCHEMBL6141483 0.85 ADRB2 (0.76) ADRB2ADRB3ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747043-B2 TREATING PULMONARY DISEASE, PRE-TERM LABOR, NEUROLOGICAL DISORDERS, CARDIAC DISORDERS, AND INFLAMMATION THERAVANCE, INC. 2004-06-08 US claimed
US-20040006102-A1 Alkoxy aryl beta2 adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2004-01-08 US claimed
US-20040006102-A1 Alkoxy aryl beta2 adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006102-A1 Alkoxy aryl beta2 adrenergic receptor agonists ADRB2, ADRB1, ADRA2C ADRB2 1/4885ADRB3 5/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.